“CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) is a revolutionary gene-editing technology adapted from a natural defence system that bacteria use to fight off viruses. By pairing a programmable guide RNA with a specialised enzyme like Cas9, scientists can precisely target, cut, and modify specific sequences of DNA within a genome.” – CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) – Biology
The central significance of CRISPR lies in the separation of recognition from cutting. A researcher can alter the sequence of a guide RNA so that it pairs with a chosen stretch of DNA, while a CRISPR-associated protein performs the chemical work of cleavage. This makes genome editing programmable rather than dependent on designing a new protein for every target. The result is not perfect control, however. The guide, enzyme, delivery system and cell-repair pathway jointly determine what actually happens after the DNA is cut.
In bacteria, CRISPR systems form part of an adaptive defence against viruses. Short fragments of invading viral DNA can be stored between repeated sequences in the bacterial genome. When a related virus returns, RNA produced from this region helps a Cas protein recognise matching genetic material and destroy it. Laboratory methods adapted this arrangement by combining a targeting RNA with an enzyme such as Cas9. The guide RNA supplies sequence recognition, while Cas9 cuts both strands of DNA near the matching site, provided the target also satisfies the enzyme’s neighbouring sequence requirements.6
That mechanism supports several distinct editing outcomes. If the cell repairs a double-strand break through non-homologous end joining, small insertions or deletions may disrupt a gene. If a repair template is supplied, homology-directed repair can introduce a specified sequence, although this pathway is often inefficient and depends strongly on cell type and cell-cycle state. Newer systems avoid cutting both DNA strands: base editors chemically convert one DNA base into another, while prime editors use a modified guide and reverse-transcriptase activity to write a broader range of changes. These approaches reduce some risks but introduce their own constraints and possible unintended edits.
Precision therefore has a practical rather than absolute meaning. A guide RNA may bind a near-match elsewhere in the genome, producing an off-target alteration. Even at the intended site, repair can create larger deletions, rearrangements or mixtures of edited and unedited cells. A review in Nature Communications notes that CRISPR systems can generate both intended and unintended genetic changes, including rare chromosomal events that could matter if affected cells expand in the body.3 Safety assessment consequently requires sequencing and functional testing beyond checking whether the intended nucleotide change is present.
From molecular tool to medical treatment
The most advanced clinical use has been ex vivo editing, in which cells are removed from a patient, modified in a controlled laboratory process and then returned. Casgevy, approved by the US Food and Drug Administration for eligible patients with sickle cell disease and later expanded indications, uses the patient’s own blood stem cells. CRISPR editing alters an enhancer associated with BCL11A, reducing its repression of fetal haemoglobin production. Higher fetal haemoglobin can lessen the tendency of red blood cells to sickle, addressing a major biological driver of painful vaso-occlusive crises.2
This treatment illustrates both the promise and the burden of genome editing. The edited cells must be collected, processed, quality-tested and reinfused after conditioning that clears space in the bone marrow. It is therefore not a simple injection of molecular scissors. The treatment can be transformative for appropriately selected patients, but manufacturing complexity, specialised clinical infrastructure, long-term monitoring and cost limit immediate access. The UK regulator became the first national regulator to approve Casgevy in November 2023, followed by US approval the next month, marking a regulatory milestone without proving that CRISPR is broadly safe for every disease.12
In vivo editing presents a different challenge because the editing components must reach the correct tissue inside the body. Viral vectors, lipid nanoparticles and other carriers can transport guide RNA and editing proteins, but they differ in distribution, immune response, duration and capacity. Delivery to the liver is comparatively tractable for some approaches; reaching the brain, muscle, lung or scattered tumour cells is more difficult. A recent review identifies limited packaging capacity of certain viral vectors and immune responses to both carriers and CRISPR components as continuing obstacles.13 A useful therapy must therefore solve delivery and biological specificity together, not merely identify a desirable gene.
Competing approaches and unresolved tensions
One school of thought treats CRISPR primarily as a precision instrument for correcting pathogenic variants. Another emphasises regulation rather than correction: changing gene expression may be safer than rewriting a faulty sequence, especially when the disease results from an overactive pathway. A third approach focuses on cell engineering, including immune cells designed to recognise cancer. These strategies differ in risk because editing a short-lived cell population, an ex vivo stem-cell population and reproductive cells have very different consequences.
The sharpest ethical boundary concerns heritable germline editing. Changes made to embryos, eggs or sperm could pass to future generations, including people who cannot consent and whose biological circumstances are unknown. Somatic editing, by contrast, is intended to affect only the treated individual. This distinction does not remove ethical questions about access, disability, enhancement or unequal distribution, but it provides a central framework for governance. The medical success of an approved somatic therapy should not be treated as a mandate for reproductive editing.
CRISPR also exposes a tension between biological precision and social simplicity. Public descriptions often call Cas9 molecular scissors, but cutting is only the first event in a chain involving DNA repair, cell selection, immune surveillance and long-term clonal behaviour. Researchers must decide how much residual risk is acceptable for a serious disease with few alternatives, how long follow-up should continue, and which outcomes count as success. A small off-target rate may be unacceptable for treating a healthy person at risk of a future condition, yet potentially acceptable when treating a life-threatening disorder, subject to evidence and oversight.
CRISPR remains important because it has made genetic intervention faster to design, easier to adapt and applicable across research, agriculture and medicine. It enables functional experiments in which genes are disrupted, activated or tagged to test their roles in living systems. It also provides a platform rather than one fixed technology: nuclease editing, base editing, prime editing, epigenetic regulation and RNA targeting each address different weaknesses. The enduring question is not whether CRISPR can edit DNA, but whether a particular system can reach the right cells, make the right change, avoid damaging alternatives and deliver a benefit that outweighs its clinical, economic and ethical costs.3
References
1. FDA Approves First Gene Therapy for Young Children with … – 2026-01-07 – https://www.fda.gov/news-events/press-announcements/fda-approves-first-gene-therapy-young-children-sickle-cell-disease
2. FDA Approves First Gene Therapies to Treat Patients with … – 2023-12-08 – https://www.fda.gov/news-events/press-announcements/fda-approves-first-gene-therapies-treat-patients-sickle-cell-disease
3. Assessing and advancing the safety of CRISPR-Cas tools: from DNA to RNA editing – 2023-01-13 – https://www.nature.com/articles/s41467-023-35886-6
4. Vertex Announces US FDA Approval for Expanded Use of … – 2026-07-01 – https://news.vrtx.com/news-releases/news-release-details/vertex-announces-us-fda-approval-expanded-use-casgevyr-treatment
5. Casgevy: First CRISPR gene-editing treatment approved in U.S. – 2023-12-08 – https://www.cnbc.com/2023/12/08/casgevy-first-crispr-gene-editing-treatment-approved-in-us.html
6. nigms.nih.gov › biobeat › 2024What Is CRISPR? – National Institute of General Medical Sciences – https://nigms.nih.gov/biobeat/2024/10/what-is-crispr
7. Gene editing and CRISPR-dependent homology-mediated end joining – 2025-07-31 – https://www.nature.com/articles/s12276-025-01442-z
8. www.nbcnews.com · health · health-newsFDA approves cure for sickle cell disease, the first … – 2023-12-08 – https://www.nbcnews.com/health/health-news/fda-approves-cure-sickle-cell-disease-first-treatment-use-gene-editing-rcna127979
9. MED.00146 Gene Therapy for Sickle Cell Disease – 2026-08-27 – https://www.anthem.com/medpolicies/abc/active/mp_pw_e002738.html
10. Vertex and CRISPR Therapeutics Announce US FDA Approval of … – 2023-12-08 – https://news.vrtx.com/news-releases/news-release-details/vertex-and-crispr-therapeutics-announce-us-fda-approval
11. US FDA approves two gene therapies for sickle cell disease – 2023-12-08 – https://www.reuters.com/business/healthcare-pharmaceuticals/us-approves-two-gene-therapies-sickle-cell-disease-2023-12-08/
12. Editorial: First Regulatory Approvals for CRISPR-Cas9 Therapeutic … – 2024-03-01 – https://pmc.ncbi.nlm.nih.gov/articles/PMC10913280/
13. Therapeutic in vivo genome editing: innovations and challenges in rAAV vector-based CRISPR delivery – 2025-11-12 – https://www.nature.com/articles/s41434-025-00573-2
14. CRISPR/Cas9 therapeutics: progress and prospects – 2023-01-16 – https://www.nature.com/articles/s41392-023-01309-7
15. Spatiotemporal control of CRISPR/Cas9 gene editing – Signal Transduction and Targeted Therapy – 2021-06-20 – https://www.nature.com/articles/s41392-021-00645-w
